Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors

Diseases and Conditions Researched

Schizophrenia; Smoking

What is the purpose of this trial?

The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced elevated ACh levels will lead to a reduction in the availability of nicotinic receptors for the binding of the radioligand. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects with schizophrenia, but the extent of this change will be different than in controls.


Participation Guidelines

Age: 18 Years - 60 Years
Gender: Both

This trial accepts healthy volunteers.

Click here for detailed participation information for this trial.

Sponsor: National Institute on Drug Abuse
Dates:
Last Updated:
Study HIC#: 1210010989